Does Rallies show 13F holders for SGMT?

Yes. Rallies tracks hedge fund and 13F ownership data for SGMT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SGMT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SGMT. It does not provide personalized investment advice.

SGMT (Sagimet Biosciences Inc. Series A Common Stock) Stock Analysis - Hedge Fund Holdings

Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a publicly traded Healthcare sector company. As of May 21, 2026, SGMT trades at $6.61 with a market cap of $411.27M and a P/E ratio of -4.19. SGMT moved +1.83% today. Year to date, SGMT is +20.04%; over the trailing twelve months it is +93.88%. Its 52-week range spans $1.73 to $11.41. Analyst consensus is strong buy with an average price target of $27.50. Rallies surfaces SGMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SGMT stock?

Hedge funds tracked by Rallies that own SGMT include Panagora Asset. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Sagimet Biosciences Inc. Series A Common Stock.

SGMT Key Metrics

Key financial metrics for SGMT
Metric	Value
Price	$6.61
Market Cap	$411.27M
P/E Ratio	-4.19
EPS	$-1.58
Dividend Yield	0.00%
52-Week High	$11.41
52-Week Low	$1.73
Volume	2.67K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-51.04M
Gross Margin	0.00%

Top Hedge Funds Holding SGMT

Panagora Asset holds 102.19K shares of SGMT, changed +0.00% as of Sep 30, 2024.

Latest SGMT News

Sagimet Biosciences Raises $175M, Funds Operations Through 2028 Ahead of Denifanstat Phase 3 Trial — May 12, 2026
Sagimet to launch U.S. Phase 3 denifanstat trial H2 2026 after positive China data — Apr 27, 2026
Sagimet Biosciences Names Andreas Grauer CMO, Grants $1.34M Stock Options — Apr 20, 2026
Sagimet to Present Phase 2b Data Showing 26-Week Bile Acid Reductions in MASH — Apr 6, 2026
Sagimet Secures $113M Cash, Advances Denifanstat Combo to Phase 2 MASH; Acne NDA Accepted — Mar 11, 2026

Recent SGMT Insider Trades

Happel David sold 12.10K (~$64.86K) on Feb 10, 2026.
Chauche Thierry sold 1.31K (~$7.03K) on Feb 10, 2026.
Martins Eduardo Bruno sold 3.64K (~$19.51K) on Feb 10, 2026.

SGMT Analyst Consensus

10 analysts cover SGMT: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.50.

Common questions about SGMT

Who owns SGMT stock?: Hedge funds tracked by Rallies that own SGMT include Panagora Asset. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Sagimet Biosciences Inc. Series A Common Stock.
Does Rallies show 13F holders for SGMT?: Yes. Rallies tracks hedge fund and 13F ownership data for SGMT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SGMT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SGMT. It does not provide personalized investment advice.